Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
The kit is developed for quantitative detection of natural and recombinant human TSLP in serum, plasma and cell culture supernatants.
It is for research use only.
Assay Type | Sandwich-ELISA |
Analyte | TSLP |
Format | 96-wells plate breakable into 12 x 8 wells strips |
Reactivity | Human |
Sensitivity | <31.25pg/mL |
Assay Time | 1 hr 45 min |
Sample volume | 50 uL |
Range | 31.25 pg/mL-2000 pg/mL |
Sample Type | Cell Culture Supernatants, Plasma, Serum. |
Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.
For each experiment, a standard curve needs to be set for each microplate, and the specific OD value may vary depending on different laboratories, testers, or equipment. The following example data is for reference only. The sample concentration was calculated based on the results of the standard curve. The minimum detectable concentration of TSLP is less than 31.25 pg/mL.
Ten replicates of each of 4 samples containing different TSLP concentrations were tested in one assay. Acceptable criteria: CV<10%.
Five samples containing different concentrations of TSLP were tested in independent assays. Acceptable criteria: CV<15%.
Recombinant TSLP was spiked into 3 human serum samples, and then analyzed. The average recovery of TSLP for serum samples is 91.5%.
ID | Components | Size |
CEA074-C01 | Pre-coated Anti-TSLP Antibody Microplate | 1 plate |
CEA074-C02 | Human TSLP Standard | 20 ug×2 |
CEA074-C03 | Biotin-Anti-TSLP Antibody Con. Solution | 100 μL |
CEA074-C04 | Biotin-Antibody Dilution Buffer | 8 mL |
CEA074-C05 | Streptavidin-HRP Con. Solution | 500 μL |
CEA074-C06 | Streptavidin-HRP Dilution Buffer | 15 mL |
CEA074-C07 | 20× Washing Buffer | 50 mL |
CEA074-C08 | Sample Dilution Buffer | 15 mL×2 |
CEA074-C09 | Substrate Solution | 12 mL |
CEA074-C10 | Stop Solution | 6 mL |
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tezepelumab | AMG-157; MEDI-9929 | Approved | Amgen Inc | Tezspire | United States | Asthma | Astrazeneca Ab | 2021-12-17 | Eosinophilic Esophagitis; Hypersensitivity; Dermatitis, Atopic; Hypersensitivity, Immediate; Bronchial Diseases; Pulmonary Disease, Chronic Obstructive; Respiratory Hypersensitivity; Sinusitis; Asthma; Granulomatosis with Polyangiitis; Lung Diseases; Immune System Diseases; Chronic Urticaria; Respiratory Tract Diseases; Nasal Polyps; Anaphylaxis; Carcinoma; Lung Diseases, Obstructive | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Bosakitug | BSI-045B; TQC-2731; TQC2731 | Phase 3 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd | Nasal Polyps; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
Solrikitug | MK-8226; NSI-8226 | Phase 2 Clinical | Merck & Co Inc | Hypertension; Eosinophilic Esophagitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
Ecleralimab | CSJ-117; NOV-14 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
WIN-1001X | WIN-1001X | Phase 2 Clinical | Whanin Pharmaceutical Co Ltd | Nerve Degeneration; Parkinson Disease | Details |
PF-07275315 | PF-07275315 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
Lunsekimig | SAR-443765 | Phase 2 Clinical | Sanofi | Nasal Polyps; Asthma; Sinusitis; Inflammation; Dermatitis, Atopic | Details |
AZD-8630 | AZD-8630; AMG-104 | Phase 2 Clinical | Astrazeneca Plc, Amgen Inc | Asthma | Details |
TAVO-101 | TAVO-101; TAVO101 | Phase 2 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd | Dermatitis, Atopic; Hypersensitivity | Details |
SHR-1905 | SHR-1905; AIO-001; GSK-5784283 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Nasal Polyps; Respiratory Tract Diseases; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive | Details |
CM-326(Connaught Biomedical Technology) | CM326; CM-326 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Nasal Polyps; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
PF-06342674 | RN-168; PF-6342674; PF-06342674; ZB-168 | Phase 1 Clinical | Pfizer Inc | Diabetes Mellitus, Type 1; Multiple Sclerosis | Details |
HBM-9378 | HBM-9378; SKB378; SKB-378; A-378; WIN378; WIN-378 | Phase 1 Clinical | Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
HB-0056 | HB-0056; HB0056 | Phase 1 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Asthma | Details |
APG-333 | APG333; APG-333; PR018; PR-018 | Phase 1 Clinical | Apogee Therapeutics Inc | Asthma | Details |
SAR-444765 | SAR444765; SAR-444765 | Phase 1 Clinical | Sanofi | Inflammation | Details |
CM-512 | CM512; CM-512 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Nasal Polyps; Asthma; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
IBI-3002 | IBI3002; IBI-3002 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Asthma | Details |
GB-0895 | GB-0895 | Phase 1 Clinical | Generate Biomedicines Inc | Immune System Diseases; Asthma | Details |
CDX-622 | CDX-622 | Phase 1 Clinical | Celldex Therapeutics Inc | Fibrosis; Inflammation; Hypersensitivity | Details |
STSA-1201 | STSA-1201; STSA1201 | Phase 1 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Asthma | Details |
LQ043H | LQ043H | Phase 1 Clinical | Shanghai Novamab Biopharmaceuticals Co Ltd | Asthma | Details |
GR2002 | GR2002 | Phase 1 Clinical | Genrix (Shanghai) Biopharmaceutical Co Ltd | Nasal Polyps; Asthma; Sinusitis; Dermatitis, Atopic | Details |
QX-008N | QX008N; QX-008N | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
This web search service is supported by Google Inc.